3.30 MB - Academy of Medicine of Malaysia

MANAGEMENT OF HIV INFECTION IN CHILDREN
164 Masquelier B, Neau D, Chene G et al. Mechanism of virologic failure after substitution of
a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir
Immune Defic Syndr. 2001 Dec 1;28(4):309-312.
165 Tee KK, Kamarulzaman A, Ng KP. Prevalence and pattern of drug resistance mutations
among antiretroviral-treated HIV-1 patients with suboptimal virological response in
Malaysia.Med Microbiol Immunol. 2006;195(2):107-112.
166 Nolan M, Fowler MG, Mofenson LM. Antiretroviral Prophylaxis of Perinatal HIV1 transmission
and the potential impact of antiretroviral resistance. JAIDS. 2002;30:216-229.
167 Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine
resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of
human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol
076.J Infect Dis. 1998 Mar;177(3):557-564.
168 Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the
risk of maternal-infant transmission in the women and infants transmission study. The
Women and Infants Transmission Study Group. AIDS. 2000;14(3):263-271.
169 Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant
human immunodeficiency virus type 1-infected women and their newborns in the United
States: vertical transmission and clades. J Infect Dis. 2001 Nov 1;184(9):1120-1126.
170 Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to
lamivudine when combined with zidovudine in pregnancy. J Med Virol. 1999 Nov;
59(3):364-368.
171 Cunningham CK. Chaix ML. Rekacewicz C, et al Development of resistance mutations in
women receiving standard antiretroviral therapy who received intrapartum nevirapine to
prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of
pediatric AIDS clinical trials group protocol 316. Journal Infect Dis 2002;186:181-186.
172 Shet A, Berry L, Mohri H, et al Tracking the prevalence of transmitted antiretroviral
drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006 ;41(4):
439-446.
173 CASCADE Virology Collaboration. The impact on transmitted drug resistance on the
natural history of HIV infection and response to first-line therapy. AIDS. 2006 20: 21-28.
174 Perno CF, Cozzi-Lepri, Balotta C, et al. Secondary Mutations in the Protease Region of
Human Immunodeficiency Virus and Virologic Failure in Drug-Naive Patients Treated with
Protease Inhibitor–Based Therapy JID 2001;184:983-991.
175 Fox J, Dustan S, McClure M, et al. Transmitted drug-resistant HIV-1 in primary HIV-1
infection; incidence, evolution and impact on response to antiretroviral therapy. HIV
Medicine. 2006; 7(7): 477-483.
176 WHO guidelines for Surveillance of HIV Drug Resistance in newly diagnosed and
treatment –naïve HIV subjects 2003.
177 Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A
Working Group of the Office of AIDS Research Advisory Council (OARAC), October 10,
2006.
64